montelukast/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Increases forced expiratory volume in one second (FEV1)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“The random‐effects meta‐analysis demonstrated that the FEV1 was improved by montelukast adjuvant therapy with a statistical difference (SMD = 1.15, 95% CI [0.53, 1.77], P < 0.01).”
Quoted verbatim from Efficacy and safety of montelukast adjuvant therapy in adults with cough variant asthma: A systematic review and meta-analysis.. - Study
- meta-analysis
- Population
- Adults aged 18 years or older with cough variant asthma; seven RCTs pooled, montelukast added to inhaled corticosteroid plus long-acting beta agonist versus the same inhaled corticosteroid plus long-acting beta agonist alone (background therapy in both arms); high heterogeneity
Effect 1.15 standardised mean difference, 95% CI 0.53 to 1.77
Efficacy and safety of montelukast adjuvant therapy in adults with cough variant asthma: A systematic review and meta-analysis.2023PMID:37218346Permalink
Keep reading
- Everything the graph holds on montelukast
- Every compound studied against Forced expiratory volume in one second (FEV1)
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M45CHKCEST75ZWRYBV5QRRCS